Latest Insider Transactions at Natera, Inc. (NTRA)
This section provides a real-time view of insider transactions for Natera, Inc. (NTRA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Natera, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Natera, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 23
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Bona fide gift
|
Direct |
81
-0.07%
|
-
|
|
Dec 19
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Bona fide gift
|
Direct |
125
-0.11%
|
-
|
|
Dec 18
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
2,148
-0.91%
|
$358,716
$167.09 P/Share
|
|
Dec 18
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
852
-1.79%
|
$142,284
$167.07 P/Share
|
|
Dec 18
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
2,700
-0.35%
|
$450,900
$167.12 P/Share
|
|
Dec 13
2024
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Direct |
160,000
-1.28%
|
$26,560,000
$166.45 P/Share
|
|
Dec 10
2024
|
Rowan E Chapman |
SELL
Open market or private sale
|
Direct |
1,767
-22.17%
|
$300,390
$170.24 P/Share
|
|
Dec 09
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
4,858
-4.06%
|
$806,428
$166.59 P/Share
|
|
Dec 09
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
BUY
Grant, award, or other acquisition
|
Direct |
9,075
+3.7%
|
$90,750
$10.15 P/Share
|
|
Dec 05
2024
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
BUY
Exercise of conversion of derivative security
|
Direct |
68,496
+2.62%
|
$342,480
$5.4 P/Share
|
|
Dec 02
2024
|
Roelof Botha Director |
SELL
Open market or private sale
|
Indirect |
87,473
-1.37%
|
$14,695,464
$168.7 P/Share
|
|
Nov 26
2024
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
2,000
-0.78%
|
$328,000
$164.35 P/Share
|
|
Nov 25
2024
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
2,000
-0.76%
|
$336,000
$168.91 P/Share
|
|
Nov 19
2024
|
Gail Boxer Marcus |
SELL
Open market or private sale
|
Direct |
9,682
-28.45%
|
$1,549,120
$160.18 P/Share
|
|
Nov 15
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
4,628
-0.49%
|
$680,316
$147.3 P/Share
|
|
Nov 15
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
100
-0.05%
|
$14,600
$146.35 P/Share
|
|
Nov 15
2024
|
Roy D. Baynes |
SELL
Open market or private sale
|
Direct |
37,230
-17.42%
|
$5,435,580
$146.96 P/Share
|
|
Nov 15
2024
|
Roy D. Baynes |
BUY
Exercise of conversion of derivative security
|
Direct |
37,230
+29.55%
|
$856,290
$23.63 P/Share
|
|
Nov 14
2024
|
Gail Boxer Marcus |
SELL
Open market or private sale
|
Direct |
2,212
-2.13%
|
$351,708
$159.14 P/Share
|
|
Nov 13
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
16,300
-5.06%
|
$2,526,500
$155.61 P/Share
|
|
Nov 13
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
20,000
-3.64%
|
$3,060,000
$153.4 P/Share
|
|
Nov 12
2024
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+0.4%
|
$50,000
$5.4 P/Share
|
|
Nov 11
2024
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
BUY
Exercise of conversion of derivative security
|
Direct |
130,000
+5.0%
|
$650,000
$5.4 P/Share
|
|
Nov 08
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
3,000
-1.05%
|
$393,000
$131.02 P/Share
|
|
Nov 08
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
2,700
-0.32%
|
$351,000
$130.84 P/Share
|
|
Oct 31
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,866
-2.64%
|
$235,116
$126.45 P/Share
|
|
Oct 29
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
754
-1.06%
|
$89,726
$119.93 P/Share
|
|
Oct 28
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,238
-1.7%
|
$146,084
$118.21 P/Share
|
|
Oct 28
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
3,960
-2.04%
|
$467,280
$118.21 P/Share
|
|
Oct 28
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
929
-0.81%
|
$109,622
$118.21 P/Share
|
|
Oct 28
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
1,196
-1.07%
|
$141,128
$118.21 P/Share
|
|
Oct 28
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,057
-0.51%
|
$124,726
$118.21 P/Share
|
|
Oct 25
2024
|
Roy D. Baynes |
BUY
Grant, award, or other acquisition
|
Direct |
124
+0.78%
|
-
|
|
Oct 25
2024
|
Roelof Botha Director |
BUY
Grant, award, or other acquisition
|
Direct |
203
+5.11%
|
-
|
|
Oct 25
2024
|
James Healy |
BUY
Grant, award, or other acquisition
|
Direct |
153
+0.33%
|
-
|
|
Oct 25
2024
|
Herm Rosenman |
BUY
Grant, award, or other acquisition
|
Direct |
178
+0.27%
|
-
|
|
Oct 25
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
691
-0.94%
|
$81,538
$118.81 P/Share
|
|
Oct 24
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
914
-1.23%
|
$108,766
$119.19 P/Share
|
|
Oct 23
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
496
-0.66%
|
$59,024
$119.09 P/Share
|
|
Oct 22
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+1.64%
|
-
|
|
Oct 22
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
199
-0.17%
|
$23,880
$120.07 P/Share
|
|
Oct 22
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
256
-0.23%
|
$30,720
$120.07 P/Share
|
|
Oct 22
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
454
-0.61%
|
$54,480
$120.07 P/Share
|
|
Oct 22
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
893
-0.46%
|
$107,160
$120.07 P/Share
|
|
Oct 22
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
349
-0.17%
|
$41,880
$120.07 P/Share
|
|
Oct 21
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
342
-0.3%
|
$41,040
$120.76 P/Share
|
|
Oct 21
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
294
-0.26%
|
$35,280
$120.76 P/Share
|
|
Oct 21
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
608
-0.81%
|
$72,960
$120.76 P/Share
|
|
Oct 21
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,145
+1.51%
|
-
|
|
Oct 21
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
1,709
-0.87%
|
$205,080
$120.76 P/Share
|